check_circleStudy Completed

Prostatic Neoplasms

Radium-223 dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients with Bone Metastases

Trial purpose

This study is a prospective, interventional, open-label, multi-center early access program for the use of Ra-223 Cl2 in HRPC/CRPC patients diagnosed with symptomatic bone metastasis and to collect additional short and long term safety data on the product.

Key Participants Requirements

Sex

Male

Age

18 - N/A

Trial summary

Enrollment Goal
N/A
Trial Dates
null - Today
Phase
N/A
Could I Receive a placebo
No
Products
Xofigo (Radium-223 dichloride, BAY88-8223)
Accepts Healthy Volunteer
N/A

Where to participate

StatusInstitutionLocation
Completed
New Orleans, 70112, United States
Completed
Tampa, 33612, United States
Completed
Las Vegas, 89169, United States
Completed
Stanford, 94305, United States
Withdrawn
St. Louis, 63110, United States
Withdrawn
Houston, 77030, United States
Withdrawn
Myrtle Beach, 29572, United States
Completed
Scottsdale, 85260, United States
Completed
Boston, 02215, United States
Withdrawn
Houston, 77030, United States
Withdrawn
Pittsburgh, 15213, United States
Completed
Wheeling, 26003, United States
Completed
Philadelphia, 19107, United States
Completed
Fort Myers, 33901, United States
Completed
Boston, 02114, United States
Completed
Rockville, 20850, United States
Withdrawn
Aurora, 80045, United States
Completed
Philadelphia, 19111-2497, United States
Withdrawn
San Francisco, 94143, United States
Withdrawn
Detroit, 48201, United States
Completed
Goshen, 46526, United States
Completed
New York, 10065, United States
Withdrawn
Bethesda, 20889, United States
Withdrawn
Atlanta, 30322, United States
Completed
Shreveport, 71103, United States
Completed
Detroit, 48202, United States
Withdrawn
Newark, 19718, United States
Completed
Baltimore, 21229, United States
Completed
New Hyde Park, 11040-1496, United States
Withdrawn
New Brunswick, 08903-2681, United States
Completed
Phoenix, 85040, United States
Withdrawn
Honolulu, 96813-2413, United States
Completed
Iowa City, 52242, United States
Withdrawn
Durham, 27710, United States
Withdrawn
Ann Arbor, 48109-0028, United States
Completed
Cleveland, 44195, United States
Withdrawn
Plano, 75093, United States
Completed
Miami Beach, 33140, United States
Completed
Minneapolis, 55455, United States
Withdrawn
Greenbrae, 94904, United States
Withdrawn
Washington, 20060, United States
Withdrawn
Birmingham, 35233, United States
Withdrawn
Raleigh, 27607, United States
Withdrawn
Washington, 20007, United States
Withdrawn
Norfolk, 23507, United States
Withdrawn
Milwaukee, 53226-3596, United States
Withdrawn
Columbus, 43212, United States
Withdrawn
San Antonio, 78229, United States
Completed
Boston, 02215, United States
Completed
Temple, 76508, United States
Completed
Myrtle Beach, 29577, United States
Withdrawn
Baltimore, 21287, United States
Withdrawn
Baltimore, 21201-1595, United States
Withdrawn
Nashville, 37232, United States
Withdrawn
Seattle, 98122, United States
Withdrawn
La Jolla, 92093, United States
Withdrawn
Philadelphia, 19401, United States
Withdrawn
Newark, 07103, United States
Withdrawn
Springfield, 97477, United States
Withdrawn
New York, 10016, United States
Withdrawn
Hampton, 23666, United States
Withdrawn
Syracuse, 13210, United States

Trial design

Radium-223 Chloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients with Bone Metastases
Trial Type
Expanded Access
Intervention Type
Drug
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A